Trials of antidepressants for children consistently exaggerated their benefits while playing down their possible harm

Antidepressants should not be used to treat children and teenagers, a controversial new Australian study has warned, saying clinical trials have exaggerated the benefits of the drugs and played down their side effects.

However, doctors are split over the findings, arguing that the drugs have a valid place in the treatment of young people.

The Australian study, published in the British Medical Journal, found trials of antidepressants such as Zoloft, Prozac, Arapax, Efexor and Cipramil for children consistently exaggerated their benefits while playing down their possible harm.

The study also found drug companies had either paid for the trials or remunerated the authors of at least three of four larger studies.

Jon Jureidini, the study's lead author, said the findings showed antidepressants could not confidently be recommended as a treatment for children.

This follows international concern that the use of selective serotonin reuptake inhibitor antidepressants (SSRIs) to treat childhood and adolescent depression is linked to increased suicide risk and self-harm.

But other experts warned against an over-simplistic approach, arguing that the use of antidepressants depended on the treatment options available.

In younger children, the evidence on antidepressant use was not as clear and he believed the prescription of the drugs was best left to psychiatrists with experience in treating children.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Experts identify five elements of brain-based visual impairment in children